TEVJF — TEVA PHARMACEUTICAL INDUSTRIES LTD
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 818686 ·
Israel
Last close
$28.40
Market Cap
$33.07B
52W High
$37.00
52W Low
$28.40
ADV30
10
Next earnings
2026-07-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 3,981,000,000 | 1,972,000,000 | 759,000,000 | 369,000,000 | 40,040,000,000 | 3,741,000,000 | 31,808,000,000 |
| Dec 2025 | 4,711,000,000 | 2,656,000,000 | 1,269,000,000 | 480,000,000 | 40,748,000,000 | 3,556,000,000 | 32,834,000,000 |
| Sep 2025 | 4,480,000,000 | 2,304,000,000 | 1,075,000,000 | 433,000,000 | 39,856,000,000 | 2,203,000,000 | 32,602,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,714,000,000
Investing CF
$765,000,000
Financing CF
$-394,000,000
CapEx
$-542,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.14
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-13,394,000,000
Inventory
$3,176,000,000
Receivables
$3,393,000,000
ST Investments
—
EBIT TTM
$2,271,000,000
Pretax Income TTM
$1,366,000,000
Interest Exp TTM
$905,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$17,315,000,320
EBITDA
$4,268,000,000
Free Cash Flow
$2,219,875,072
Enterprise Value
$46,337,409,024
Total Cash
$3,655,000,064
Total Debt
$16,894,000,128
Shares Out
1,164,426,972
Trailing EPS
$0.60
Book Value
$6.65
ROE
9.7%
ROA
5.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 17,257,000,000 | 3,952,000,000 | 1,410,000,000 | 40,748,000,000 | 32,834,000,000 | — | 1,649,000,000 |
| Dec 2024 | 16,544,000,000 | 3,364,000,000 | -1,639,000,000 | 39,326,000,000 | 33,606,000,000 | — | 1,247,000,000 |
| Dec 2023 | 15,845,000,000 | 3,194,000,000 | -559,000,000 | 43,479,000,000 | 35,353,000,000 | — | 1,368,000,000 |
| Dec 2022 | 14,925,000,000 | 2,690,000,000 | -2,446,000,000 | 44,011,000,000 | 35,413,000,000 | — | 1,590,000,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZTS | Zoetis Inc. | $32.40B | $77.29 | — |
| ONC | BeOne Medicines Ltd. | $29.99B | $316.01 | — |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $27.44B | $205.52 | — |
| BEIGF | BeOne Medicines Ltd. | $27.08B | $21.95 | — |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $40.77B | $35.01 | — |
News headlines (Yahoo Finance, 1h cache)
Teva (TEVA) Lifts UZEDY Outlook After Record Sales And New FDA Progress
2026-07-30 17:07 · Yahoo
Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises
2026-07-30 16:21 · Yahoo
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | Delve
2026-07-30 14:31 · Yahoo
Is Teva Pharmaceutical Industries (TEVA) A Bargain After Results And Higher Revenue Guidance?
2026-07-30 12:08 · Yahoo
Teva Pharmaceutical Industries Q2 Earnings Call Highlights
2026-07-30 12:03 · Yahoo
Is Teva (TEVA) Trading Profit for Future Potential With Its Branded‑Drug Pivot?
2026-07-30 11:10 · Yahoo
Teva CEO on Drug Pipeline, Direct Listing on NYSE
2026-07-29 23:58 · Yahoo
Teva Stock Rises After Earnings as Revenue Guidance Exceeds Expectations
2026-07-29 19:10 · Yahoo
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Highlights: Strong Innovative ...
2026-07-29 19:03 · Yahoo
Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views
2026-07-29 17:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.